Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Nuvalent, Inc. NUVL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$137.44
+31.2%

Nuvalent, Inc. (NUVL) is a Biotechnology company in the Healthcare sector, currently trading at $104.75. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is NUVL = $137 (+31.2% upside).

Valuation: NUVL trades at a trailing Price-to-Earnings (P/E) of -18.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.8.

Net income is $425M (loss), growing at -74.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $1.2B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 15.27 (strong liquidity). Debt-to-assets is 0%. Total assets: $1.4B.

Analyst outlook: 14 / 14 analysts rate NUVL as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 84/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$137.44
▲ 31.21% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Nuvalent, Inc., the average price target is $137.44, with a high forecast of $155.00, and a low forecast of $120.00.
Highest Price Target
$155.00
Average Price Target
$137.44
Lowest Price Target
$120.00

NUVL SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 84/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NUVL

✓
VALUE Pass
84/100
NUVL trades at a trailing Price-to-Earnings (P/E) of -18.5 (S&P 500 average ~25). Forward PEG 0.8 — Peter Lynch undervalued (≤1.0). Trailing PEG 1.85. Analyst consensus target is $137, implying +30.8% from the current price $105. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
NUVL: +0%/yr revenue is, -74.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet NUVL: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 15.27 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
NUVL: Gross margin is 0% (+0 pp trend), $8B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 14 / 14 analysts rate NUVL as buy (100%). Analyst consensus target is $137 (+30.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range55.535-113.015
Volume592.93K
Avg Volume (30D)636.55K
Market Cap$7.67B
Beta (1Y)1.31
Share Statistics
EPS (TTM)-5.85
Shares Outstanding$72.69M
IPO Date2021-07-29
Employees162
CEOJames R. Porter
Financial Highlights & Ratios
EBITDA$-10.49M
Net Income$-425.38M
Operating Income$-414.31M
Total Cash$1.37B
Net Debt$-261.75M
Total Assets$1.41B
Price / Earnings (P/E)-17.9
Analyst Forecast
1Y Price Target$135.00
Target High$155.00
Target Low$120.00
Upside+28.9%
Rating ConsensusBuy
Analysts Covering14
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS6707031075

Price Chart

Track all markets on TradingView
NUVL
Nuvalent, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
55.54 52WK RANGE 113.02

People Also View

UTHR
UTHR
United Therapeutics Corporation
$577.58
-0.17%
 ASND
ASND
Ascendis Pharma A/S
$241.71
-3.25%
 PCVX
PCVX
Vaxcyte, Inc.
$60.45
-3.68%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 ACLX
ACLX
Arcellx, Inc.
$115.00
+0.10%
 TVTX
TVTX
Travere Therapeutics, Inc.
$40.95
-2.80%
 KNSA
KNSA
Kiniksa Pharmaceuticals, Ltd.
$45.89
-2.20%
 GPCR
GPCR
Structure Therapeutics Inc.
$54.25
+1.94%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message